Background:  Members of the LDL receptor gene family, including LDLR (low density lipoprotein receptor), LRP (low density lipoprotein related protein), Megalin (also designated GP330), VLDLR (very low density lipoprotein receptor) and ApoER2, are characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar domain. LRP, also designated a-2-Macroglobulin receptor, is an endocytic receptor that mediates the uptake of at least 15 ligands, including a-2-Macroglobulin and apoE. LRP is cleaved into a membrane subunit and an extracellular subunit, which remain non-covalently associated. Proper folding and trafficking of LRP is facilitated by the receptor-associated protein (RAP), a molecular chaperone. The uptake of all known ligands through LRP can be blocked by RAP, which induces a conformational change in the receptor that renders it unable to bind ligands. LRP, which is expressed in brain, liver and lung, is also implicated in Alzheimer’s disease (AD), as the human LRP gene localizes to a potential AD locus on chromosome 12.

Description: Rabbit polyclonal to LRPAP1

Immunogen: KLH conjugated synthetic peptide derived from LRPAP1

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 41 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.